好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Apathy Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial
Movement Disorders
P8 - Poster Session 8 (11:45 AM-12:45 PM)
5-001

To determine frequency and predictors of both improvement and worsening of apathy in participants receiving bilateral subthalamic deep brain stimulation (STN-DBS) for treatment of Parkinson’s Disease (PD) as part of the INTREPID randomized controlled trial.

Many studies have suggested that apathy can be associated with dopaminergic denervation and can possibly be unmasked by drug withdrawal and by aggressive drug tapering following STN-DBS surgery. Additionally, it has been suspected that stimulation of the limbic-associative sub-regions of the STN might serve as a catalyst, an independent cause or act synergistically with dopaminergic medication reduction.

INTREPID (ClinicalTrials.gov: NCT01839396) is a multi-center, prospective, double-blinded, randomized controlled trial. Participants with advanced PD received bilateral STN-DBS and completed a neuropsychological battery at screening (prior to DBS) and at follow up (12-months). Apathy was assessed using the Starkstein Apathy Scale (SAS). Demographic and clinical data including age, gender, disease duration, disease severity, levodopa-equivalent daily dose (LEDD), and  imaging correlates of DBS (including location and volume of stimulated tissue) were analyzed.

There were a total of 160 subjects evaluated at 1-year following STN-DBS, 44 (27.5%) reported an improvement in apathy scores of at least 5-points, and 7 (4.4%) an improvement >10 points. Eighteen (11.3%) participants had worsening apathy scores > 5 points, and 8 (5%) reported worsening > 10 points. Aggregation of stimulation field models (SFM) across the cohorts, indicated that worsening of apathy was associated with activation of limbic and associative areas of STN.

Bilateral STN-DBS in a large and prospective dataset revealed both improvement and worsening of apathy at 1-year follow-up visits. Further analysis of LEDD, dopamine agonist use, and volume of tissue activation may help us to understand the clinical factors underpinning apathy following DBS. Appropriate counseling preoperatively coupled with post-operative monitoring will be important for setting expectations and for employing appropriate treatment when necessary.

Authors/Disclosures
Tamara Stiep, MD (UCSF Movement Disorders Clinic)
PRESENTER
Dr. Stiep has nothing to disclose.
Adolfo Ramirez Zamora, MD (University of Louisville) Dr. Ramirez Zamora has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel therapeutics. Dr. Ramirez Zamora has received personal compensation in the range of $0-$499 for serving as a Consultant for NeuroPacs. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iota Inc. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Maplight. Dr. Ramirez Zamora has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. The institution of Dr. Ramirez Zamora has received research support from Parkinsons Foundation.
Alexander I. Troster, PhD (Barrow Neurological Institute) Dr. Troster has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Troster has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Troster has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage Therapeutics. Dr. Troster has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cambridge University Press/International Neuropsychological Society. The institution of Dr. Troster has received research support from Barrow Neurological Foundation. Dr. Troster has received publishing royalties from a publication relating to health care.
Roshini Jain Roshini Jain has received personal compensation for serving as an employee of Boston Scientific. Roshini Jain has received stock or an ownership interest from Boston Scientific.
Lilly Chen (Boston Scientific) Lilly Chen has received personal compensation for serving as an employee of Boston Scientific .
No disclosure on file
Michael S. Okun, MD, FAAN (University of Florida) Dr. Okun has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Okun has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Parkinson's Foundation. Dr. Okun has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Okun has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch. The institution of Dr. Okun has received research support from NIH. The institution of Dr. Okun has received research support from Parkinson's Foundation. The institution of Dr. Okun has received research support from Tourette Association of America. The institution of Dr. Okun has received research support from Michael J Fox. Dr. Okun has received publishing royalties from a publication relating to health care.